Zolbetuximab
Zolbetuximab is a chimeric monoclonal antibody targeting Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed on gastric and gastroesophageal junction tumor cells, that mediates antitumor activity through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) upon CLDN18.2 binding. It is approved in combination with chemotherapy for first-line treatment of HER2-negative, CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Its targetable tumor-selective expression makes CLDN18.2 a novel antigen in upper gastrointestinal malignancies.
Therapeutische Bereiche
Pharmacokinetics (PK)
Pharmacodynamics (PD)
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Zolbetuximab is a chimeric monoclonal antibody targeting Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed on gastric and gastroesophageal junction tumor cells, that mediates antitumor activity through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) upon CLDN18.2 binding. It is approved in combination with chemotherapy for first-line treatment of HER2-negative, CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Its targetable tumor-selective expression makes CLDN18.2 a novel antigen in upper gastrointestinal malignancies.
Yes, Zolbetuximab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109427. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zolbetuximab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zolbetuximab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zolbetuximab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zolbetuximab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zolbetuximab"></drugfyi-drug>